The efficacy of triple therapy was found to be dependent on endogenous NK cells, CD8 + T cells and wild-type p53 expression in B16F10 cells with anti-PD1 therapy, further increasing cytotoxic immune cell infiltration and the conversion of the B16F10 tumor microenvironment from ‘cold’ to ‘hot’ characterized by increased expression of CXCL10, CXCL9, CCR5, CCR2, CX3CR1, IL-2, IL-15, PD1 and PDL1. The gene discussed is TP53; the disease is neoplasm.